Breaking Down Beijing Bohui Innovation Biotechnology Group Co., Ltd. Financial Health: Key Insights for Investors

As investors scrutinize Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ), the numbers demand attention: the company posted revenue of CNY 629 million in the first three quarters of 2025 (a year-on-year decline of 2.68%) with TTM revenue at CNY 768.77 million (down 23.54% YoY) and quarterly sales of CNY 202.30 million (a 10.02% drop), while profitability shows strain- a nine‑month net loss of CNY 33.62 million, quarterly net profit margin of -7.23%, EBITDA slumping 76.27% to CNY 12.46 million and EPS turning to a loss of CNY 0.0411 for the nine months; balance‑sheet and liquidity metrics raise flags too, with total debt of CNY 880.1 million vs. cash of CNY 77.3 million, net debt/equity at 42.9%, total liabilities of CNY 2.00 billion against assets of CNY 4.32 billion (debt/assets ~46.3%), yet market valuation remains elevated-market cap of CNY 5.59 billion with P/S 6.06 and P/B 3.43-while pockets of resilience and optionality appear in a CNY 3.3 billion phased investment plan for a 1,500‑ton blood products base, a 913.96% quarterly surge in free cash flow to CNY 154.44 million, and strategic exposure (≈70%) to diagnostics; read on to see how these concrete figures, debt dynamics, liquidity signals and growth investments map to risk and opportunity for investors.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Revenue Analysis

Revenue trends for Beijing Bohui Innovation Biotechnology Group Co., Ltd. show contraction across multiple horizons, driven primarily by softer demand in the blood products market (notably human albumin and intravenous immunoglobulin).

• First three quarters 2025 revenue: CNY 629.00 million (‑2.68% YoY).
• Quarter ending 30 Jun 2025 revenue: CNY 202.30 million (‑10.02% YoY).
• Trailing twelve months (TTM) revenue: CNY 768.77 million (‑23.54% YoY).
• Full-year 2024 revenue: CNY 851.69 million (‑18.53% YoY).
• Primary driver: weakened demand for blood products - declines in human albumin and IVIG sales.

• Investor implications: elevated P/S (6.06) paired with falling sales increases sensitivity to margin compression and growth recovery timelines.
• Operational focus: stabilizing albumin/IVIG volumes and addressing demand-side weaknesses will be critical to reversing revenue declines.

For additional context on the company's strategic positioning and longer-term goals, see: Mission Statement, Vision, & Core Values (2026) of Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Profitability Metrics

Key profitability indicators for Beijing Bohui Innovation Biotechnology Group Co., Ltd. show a deterioration in earnings and margins through 2025, signaling operational and/or market pressures affecting profitability.

• Nine months ended Sep 30, 2025: net loss of CNY 33.62 million vs. net income of CNY 23.72 million in the same period 2024.
• Basic loss per share (continuing operations) for the nine months ended Sep 30, 2025: CNY 0.0411 vs. basic EPS CNY 0.029 for the prior-year period.
• Quarter ended Jun 30, 2025: net profit margin of -7.23%, indicating the company incurred a loss relative to revenue that quarter.
• Quarter ended Jun 30, 2025: EBITDA of CNY 12.46 million, down 76.27% year-over-year.
• Quarter ended Jun 30, 2025: return on assets (ROA) of -0.53% and return on capital (ROC) of -0.64%.

• Negative margins and returns indicate the company is generating losses relative to sales, assets, and invested capital during reported periods.
• Sharp decline in EBITDA (-76.27% YoY for Q2 2025) suggests either margin compression, lower volumes, cost pressure, or one-off items materially affecting operating cash profitability.
• EPS swing from positive to negative year-over-year highlights earnings deterioration and potential dilution of shareholder value if losses persist.

Further context on the company's background and business model can be found here: Beijing Bohui Innovation Biotechnology Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Debt vs. Equity Structure

Key balance-sheet metrics and capital-structure signals for Beijing Bohui Innovation Biotechnology Group Co., Ltd. show material leverage and liquidity constraints that investors should weigh alongside growth prospects. Below are core figures and interpretive bullets.

• Net debt to equity: 42.9% (elevated; indicates meaningful reliance on debt after accounting for cash).
• Five-year trend in debt-to-equity: increased from 40.0% to 47.3%, reflecting a rising use of leverage over the last five years.
• Total debt (as of 30 Jun 2025): CNY 880.1 million versus cash reserves of CNY 77.3 million - net debt of CNY 802.8 million, creating short-term liquidity pressure.
• Total liabilities (30 Jun 2025): CNY 2.00 billion; total assets: CNY 4.32 billion - debt-to-assets ≈ 46.3%.
• Total equity (30 Jun 2025): CNY 2.32 billion - producing a gross debt-to-equity ratio of ≈ 86.2% (total liabilities / total equity basis) while net-debt measures are lower.
• Market valuation (26 Nov 2025): market capitalization CNY 5.59 billion; price-to-book (P/B) ≈ 3.43, signaling a market premium to book equity.

• Liquidity pressure: low cash relative to debt (CNY 77.3M vs. CNY 880.1M) raises rollover and covenant risk in stressed scenarios.
• Leverage nuance: gross debt-to-equity (86.2%) differs materially from net-debt-based metric (42.9%); investors should consider both when assessing solvency vs. market sentiment.
• Valuation vs. balance sheet: market cap/CNY 5.59B and P/B 3.43 imply investor willingness to pay a premium despite elevated leverage.

Further context on the company's history, ownership, mission and how it operates can be found here: Beijing Bohui Innovation Biotechnology Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) as of and for the quarter ending June 30, 2025:

• Current ratio (approx): current assets / current liabilities ≈ 1.00 - indicates adequate but not ample short‑term liquidity.
• Short‑term assets exceed long‑term liabilities, improving solvency profile versus long‑term obligations.
• Strong YoY improvement in cash & short‑term investments (+80.24%) paired with a large quarter cash outflow highlights timing differences between operating cash generation and financing/investing activities.

• Free cash flow surge (Q2 2025 +913.96% YoY) signals improved operating cash conversion, yet the net quarter cash decrease (-112.03M) implies material cash uses outside operating cash generation.
• With cash on hand of CNY 168.99M and current positive quarterly FCF of CNY 154.44M, annualizing the quarter yields ≈CNY 617.76M of FCF; using available cash alone implies a runway well under one year if losses or cash burn resume.

For broader context on the company's history, ownership and business model see: Beijing Bohui Innovation Biotechnology Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) Valuation Analysis

• Market capitalization: CNY 5.59 billion (as of November 26, 2025)
• Price-to-Sales (P/S): 6.06 - indicates investors pay roughly six times annual sales
• Price-to-Book (P/B): 3.43 (as of June 30, 2025) - equity priced at a substantial premium to book value
• Earnings per Share (EPS), nine months ending Sept 30, 2025: loss of CNY 0.0411 (prior year same period: EPS CNY 0.029)
• Return on Assets (ROA), quarter ending June 30, 2025: -0.53%
• Return on Capital (ROC), quarter ending June 30, 2025: -0.64%
• Beta: -0.405 - low/negative correlation with the broader market

• Premium multiples (P/S 6.06, P/B 3.43) imply strong growth expectations or perceived strategic/asset value despite current losses.
• Negative EPS and negative quarterly ROA/ROC indicate current operating underperformance relative to assets and invested capital.
• Negative beta (-0.405) suggests limited correlation with market cycles - can act as diversification but may reflect idiosyncratic volatility or liquidity issues.
• Reconciliation of premium market valuation with weak near-term profitability requires evidence of improving margins, upcoming catalysts, or valuation driven by non-operating assets or R&D pipeline potential.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) Risk Factors

• Revenue concentration: ~70% of total revenue derives from diagnostic solutions, increasing exposure to demand shifts, pricing pressure and product-specific risks.
• Limited international diversification: International sales were <10% of total revenue as of 2022, leaving the company heavily dependent on the domestic market and vulnerable to local cyclical or policy shocks.
• Regulatory dependence: The company is subject to stringent oversight by the National Medical Products Administration (NMPA) and other authorities; changes in approval pathways, clinical requirements or post-market surveillance can materially delay product launches and revenue recognition.
• High fixed-cost base: Fixed costs (R&D, compliance, facility overhead) accounted for ~65% of total operating expenses in 2022, reducing operating leverage and increasing break-even sensitivity during sales declines.
• Talent risk: Industry competition for skilled professionals is intense; the company reports a talent retention rate of ~75%, which may impede sustained innovation and operational continuity.
• Leverage and financial flexibility: Net debt to equity stands at 42.9%, reflecting notable reliance on debt financing that may constrain capital allocation and heighten vulnerability to interest-rate movements or refinancing risk.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Growth Opportunities

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) is positioning for scalable expansion through capital investment, product-line industrialization, operational efficiency and targeted R&D in automated diagnostics. Key drivers and indicators of potential growth include:

• Planned phased investment of CNY 3.3 billion to establish the Bohui Biological Shijiazhuang Modern Biopharmaceutical Industry Base, incorporating a biopharmaceutical business HQ, R&D center, and a 1,500-ton intelligent blood products production base.
• Operational improvements: implementation of cost control and lean management that yielded an increase in gross profit margin for blood products year-over-year.
• Technology leverage: focus on innovative detection solutions such as the GenPlex microfluidic automated nucleic acid detection system to address demand for automated, high-precision diagnostics.
• Market sentiment: a 16.72% increase in market capitalization over one year, reflecting positive investor outlook.
• Cash generation: free cash flow of CNY 154.44 million for the quarter ending June 30, 2025, representing a 913.96% increase year-over-year.
• Risk/return profile: a beta of -0.405, indicating low (and inverse) correlation with the broader market that can offer diversification or signal idiosyncratic risk.

Investors evaluating growth potential should weigh the capital deployment toward scale (CNY 3.3 billion) and the large production target (1,500 tons) against execution risk and the company's idiosyncratic market behavior (beta -0.405). The dramatic YoY free cash flow improvement (CNY 154.44M, +913.96%) combined with margin gains from lean initiatives supports improved cash generation while GenPlex and other R&D priorities create potential revenue diversification.

For company background and context on strategy, ownership and business model, see: Beijing Bohui Innovation Biotechnology Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money